On this episode, we're continuing our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We'll hear from three researchers about their findings in prostate cancer trials reported at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're sharing news from our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We'll hear from two researchers about their findings in renal cell carcinoma (RCC). To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're reviewing two recent U.S. Food and Drug Administration (FDA) approvals for patients with breast cancer: the February 3 approval of sacituzumab govitecan-hziy, and the January 27 approval of elacestrant. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The 2023 ASCO Gastrointestinal Cancers Symposium took place from January 19 to 21 in San Francisco. On this episode, we're hearing from the presenting authors of three studies reported at that meeting—the SUNLIGHT, SPOTLIGHT, and NAPOLI-3 trials—which examined novel regimens in colorectal cancer, gastric cancer, and pancreatic cancer, respectively. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, Professor of Surgical Oncology and Global Health at University of Nebraska Medical Center, and an editorial advisor for The ASCO Post, holds a conversation with John H. Strickler, MD, a medical oncologist at Duke University Medical Center. The topic is the safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated patients with KRAS G12C–mutated pancreatic cancer, based on Strickler et al's paper published on Jan...
On this episode, we're continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we'll hear from several researchers about their findings in lymphoma. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're continuing our coverage of research presented at the 2022 ASH Annual Meeting and Exposition. Today, we'll hear from several researchers about their findings in multiple myeloma. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're featuring authors discussing their impactful research presented at the 2022 ASH Annual Meeting and Exposition, focusing on findings in different subtypes of leukemia. To listen to more podcasts from ASCO, visit asco.org/podcasts .
This year's San Antonio Breast Cancer Symposium took place last week. On this episode, we're hearing from the authors of three high-impact studies that were presented at the meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're reviewing U.S. Food and Drug Administration (FDA) approvals in oncology and hematology that occurred during the month of November. To listen to more podcasts from ASCO, visit asco.org/podcasts .
" On this episode, we're hearing from three authors of high-impact research that was presented at the recent Annual Meeting of the Society for Immunotherapy of Cancer, or SITC. Their studies focused on immune checkpoint inhibitors for patients living with HIV and cancer, T-cell receptor T-cell therapy for patients with solid tumors, and radiation boosts plus pembrolizumab in patients with triple-negative breast cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts . "...
On this episode, we're hearing from authors of recent impactful research in the field of genitourinary oncology. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're covering two recent approvals from the U.S. Food and Drug Administration (FDA): one in unresectable hepatocellular carcinoma, and one in relapsed or refractory multiple myeloma. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're covering two studies that focused on the effects of mortgage discrimination on cancer care outcomes. The research—in colon and lung cancers—was presented during the 2022 ASCO Quality Care Symposium. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're highlighting speakers who presented data in skin cancers during the ESMO Congress 2022, including findings on tumor-infiltrating lymphocyte therapy in advanced melanoma, cemiplimab in cutaneous squamous cell carcinoma, and the association of circulating tumor DNA and disease recurrence in patients with later-stage melanoma. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The 2022 ASCO Quality Care Symposium took place in Chicago over the weekend. On this episode, we're featuring two speakers who presented data at the meeting: the first focuses on the effects of Medicaid expansion on cancer mortality rates, and the second describes efforts to improve prescribing practices for prophylactic colony stimulating factors in the treatment of neutropenia. To listen to more podcasts from ASCO, visit asco.org/podcasts ....
On this episode, we're highlighting speakers who presented data in breast cancer during the ESMO Congress 2022. The first speaker discusses patterns of genomic instability in metastatic breast cancer, and the second touches on oncofertility care for young patients with breast cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts .
The ESMO Congress 2022 took place in Paris from September 9 to 13. In this episode, we highlight key research presented at the meeting. We'll first hear from the presenting author of Abstract LBA1 on the effect of air pollutants on the risk of non–small cell lung cancer. Then, we'll hear from a researcher on the SWOG S1801 team on the benefits of different therapeutic strategies using pembrolizumab in patients with advanced melanoma. Finally, we'll hear about the results of the IMmotion 010 stud...
This week, we're covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We'll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer. Coverage of stories discussed this week on ascopost.com: FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up To listen to more p...
In this episode, we're featuring two speakers presenting data from the European Hematology Association 2022 Congress, focusing on findings in acute myeloid leukemia and diffuse large B-cell lymphoma. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're featuring discussions about data in colorectal cancer that were presented at the 2022 ASCO Annual Meeting. Dr. Michael Overman, of The University of Texas MD Anderson Cancer Center, speaks with two presenters about guiding therapy with circulating tumor DNA and refining treatment strategies for RAS wild-type metastatic disease. To listen to more podcasts from ASCO, visit asco.org/podcasts .
Dr. Courtney DiNardo, of The University of Texas MD Anderson Cancer Center, sat down with two colleagues at the 2022 ASCO Annual Meeting to discuss data presented in leukemia. On this episode of the podcast, we're featuring Dr. DiNardo's conversations. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're featuring discussions on lung cancer that took place at the 2022 ASCO Annual Meeting. They were led by Dr. Gilberto de Lima Lopes, Jr, of the Sylvester Comprehensive Cancer Center at the University of Miami. The first focuses on data from a study of a novel bispecific antibody in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation. The second focuses on an analysis of patients with lung cancer treated with chemoimmunotherapy regimens. T...
At the 2022 ASCO Annual Meeting, Dr. Ann Partridge, of Dana-Farber Cancer Institute, discussed trends in breast cancer with several colleagues. On this episode, we're featuring two of those conversations: one on antibody-drug conjugates, and another on endocrine therapy plus ribociclib for progressive breast cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts .
In this episode, we're featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube cancer. To listen to more podcasts from ASCO, visit asco.org/podcasts .
In this episode, we're featuring two conversations from leaders in the field of genitourinary oncology. These discussions go over long-term findings in prostate cancer and urothelial carcinoma, and were both presented at the 2022 ASCO Annual Meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
In this episode, we'll hear about results from the phase III DETERMINATION trial in multiple myeloma, and a study that sought to determine when radiotherapy may be avoided after breast-conserving surgery. To listen to more podcasts from ASCO, visit asco.org/podcasts .
In this episode, we continue to highlight research presented at the 2022 ASCO Annual Meeting. We'll first hear a discussion between two researchers on Plenary Abstract LBA1, which may establish a standard first-line combination regimen for patients with RAS wild-type and left-sided metastatic colorectal cancer. Then, we'll hear about a study that highlighted the need to increase participation in clinical trials amongst Black women with metastatic breast cancer. To listen to more podcasts from AS...
On this episode, we're reviewing two studies, including one plenary presentation, presented at the 2022 ASCO Annual Meeting. To listen to more podcasts from ASCO, visit asco.org/podcasts .
On this episode, we're continuing our coverage of high-impact research presented at the 2022 ASCO Annual Meeting, focusing on major studies in breast cancer and mantle cell lymphoma. To listen to more podcasts from ASCO, visit asco.org/podcasts .
